Historical cah News Stories
Cardinal Health Q3: Buybacks, Impairment Hit Stock
Cardinal Health reported mixed Q3 results: strong non-GAAP earnings and raised cash-flow guidance contrasted with a GAAP hit and a goodwill impairment. The stock dropped after the release despite aggressive buybacks and continued dividends.
Cardinal Health Q3 Beat, Guidance Lift, Selloff
Cardinal Health reported April 30 Q3 results with a non‑GAAP EPS beat and raised FY26 guidance, but a revenue miss, a $184M impairment and margin pressure sent CAH shares lower. Specialty strength (oncology, specialty pharma) contrasts with GLP‑1 and IRA headwinds; investors should track revenue mix, free cash flow and execution against guidance.
Cardinal Health Compliance Risk Fuel Stock Rebound
Cardinal Health (CAH) is showing stock recovery despite lingering regulatory and legacy liabilities. Recent updates highlight ongoing compliance scrutiny tied to past misconduct, while CAH’s share price has rebounded from last year’s lows and sits below its 52-week high. Concurrent healthcare IT deals underscore shifting competitive dynamics that may affect Cardinal’s services and margins. This article summarizes material events and their near-term implications for investors.
Cardinal Health CAH Remains Steady in S&P 500 Pulse
Cardinal Health (CAH) showed steady trading late in March as healthcare names drew defensive flows. With the Health Care Select Sector (XLV) outperforming, CAH’s scale and distribution strengths helped it weather margin pressure from generic pricing and legacy litigation. Investors should monitor upcoming quarterly results and Medical segment trends as potential catalysts.
Cardinal Health: Specialty, ContinuCare Drive CAH.
Cardinal Health (CAH) has reported recent, concrete momentum: raised FY2026 EPS guidance to at least $10, specialty pharma revenue targets above $50B, successful ADSG integration, and the rollout of the ContinuCare™ Pathway. These developments—highlighted at the Leerink conference and in investor presentations—strengthen CAH’s earnings profile, bolster analyst confidence, and support S&P 500 investor interest.
Cardinal Health Soars: Q2 Beat Fuels Buybacks Now!
Cardinal Health (CAH) surged after a strong Q2 FY2026 report that lifted guidance and continued aggressive share repurchases. Investor optimism—highlighted by a Weiss Ratings uptick—remains the short-term catalyst, while execution in specialty services and reimbursement uncertainty are primary risks. No new, material developments emerged in the most recent week.
Cardinal Health Order Express Fuels Specialty Push
Cardinal Health (CAH) bolstered its specialty and logistics positioning this week with the rollout of the Order Express high-speed logistics platform and the finalized acquisition of Specialty Networks. These concrete moves — plus renewed competitive dynamics after OptumRx contract shifts — point to revenue diversification, margin pressure alleviation, and measurable operational improvements investors should track.
Cardinal Health Climbs Near 52-Week High CAH Rally
Cardinal Health (CAH) gained 2.17% on Feb 17, 2026, closing at $225.58 and trading just below its 52-week high of $230.81. The move outpaced healthcare peers amid a modest S&P 500 uptick; trading volume was slightly below the 50-day average. No other major sector-specific headlines emerged in the past week, leaving technical momentum and upcoming catalysts as primary drivers for investors.
Cardinal Health Ups FY26 EPS Outlook to $10+
Cardinal Health raised its FY2026 non‑GAAP EPS guidance to at least $10, citing strong Specialty and BioPharma growth, broad ContinuCare rollout, and successful contract transitions ahead of Medicare drug‑pricing changes—key developments that materially affect CAH shares.
Cardinal Health Surges: Q2 Beat, Guidance Raised!!
Cardinal Health (CAH) reported a strong Q2 FY2026 with a revenue beat, raised full-year EPS guidance, and signaled continued growth from higher-margin specialty services (Sonexus, BioPharma). Technical strength (RS Rating 91) and aggressive capital returns contrast with elevated debt and $4.3B opioid liabilities.